Fig. 2

a Distribution of minimum inhibitory concentration (MIC) of teicoplanin in the initial teicoplanin treatment (n = 28) and ß-lactam treatment (n = 56) groups. In total, 78.6% (22/28) of patients in the initial teicoplanin treatment group with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia had teicoplanin MICs < 1.5 mg/L and 60.7% (34/56) of patients in the initial ß-lactam treatment group with MSSA bacteremia had teicoplanin MICs < 1.5 mg/L. b Distribution of minimum inhibitory concentration (MIC) of teicoplanin in the initial teicoplanin treatment (n = 28) and ß-lactam treatment (n = 28) in propensity-matched group. 78.6% (22/28) of patients in the initial teicoplanin treatment group with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia had teicoplanin MICs < 1.5 mg/L and 67.9% (19/28) of patients in the initial ß-lactam treatment group with MSSA bacteremia had teicoplanin MICs < 1.5 mg/L